A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-12-20

Summary

This is an open-label, multicentre, randomized phase II non-inferiority trial aiming to compare the efficacy and safety of 4 versus 6 cycles of CHP (administered at 21-day intervals), both in combination with 6 cycles of polatuzumab vedotin and rituximab, in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) and an International Prognostic Index (IPI) score of 0-1. The study's primary objective is to determine if shorter CHP duration can achieve comparable outcomes to the standard 6-cycle regimen when combined with polatuzumab vedotin and rituximab

• Phase: PHASE2

Details

• Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China
• Treatments: Cyclophosphamide; Doxorubicin; polatuzumab vedotin; Prednisone; Rituximab